An interventional study of Brain functional MRI with simplified urodynamics in Urgency Urinary Incontinence, sponsored by University of Pittsburgh. Completed at 1 site in United States. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-05.
Sponsored by University of Pittsburgh · Not applicable, Interventional, and Other
How we know · 2 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 293 studies in Urinary Incontinence with a site in United States — 33 open to participants now, 47 under way, 3 of them phase 3. Urinary Incontinence · United States.
Among the 293 studies in Urinary Incontinence with a site in United States, this one is the 61st largest by enrollment of the 249 interventional ones that give a count, is one of 14 that started in 2020, is one of 144 with no phase, and was the 213th registered.
988 studies on the registry are indexed under Urinary Incontinence; 184 are open to participants now.
Browse Urinary Incontinence studies →33 of the 293 studies in Urinary Incontinence with a site in United States are open now. Recruiting first, the newest first:
Pfizer · Sites in United States, Canada
Ages 18+ · Women only
Duke University · Sites in United States
Ages 18+ · Men only
Ohio State University · Sites in United States
Ages 18+ · Women only
The Methodist Hospital Research Institute · Sites in United States
Ages 22–80 · Men only · Healthy volunteers
University of Miami · Sites in United States
Ages 18+ · Women only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 113 Urinary Incontinence studies recruiting now, 63 (56%) set no upper age limit and 35 (31%) stop at 75 or younger; 15 take children under 18; 28 take healthy volunteers.
This study: 18 Years and older · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
293 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 20 · Phase 2 23 · Phase 3 38 · Phase 4 35
First in 1993; this study’s year is marked. 14 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 217 is above the median of 66 across 743 interventional studies indexed under Urinary Incontinence.
Median enrollment 75 across the 249 interventional studies, 100 across the 43 observational. Of the 219 that completed or were terminated, 105 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
87 of 293 have an industry lead sponsor. The 10 most frequent:
University of Pittsburgh is the lead sponsor of 1,422 studies on the registry; 170 are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 4 (44%) have results posted.
University of Pittsburgh has 3 studies filed under Urinary Incontinence — fewer than ten, so there is no comparison to draw.
16 of the studies in Urinary Incontinence with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07387315TriHealth Inc.A Randomized, Placebo-controlled Trial of Nitrous Oxide During In-office Bladder Botox Injections | 2026-11 |
| NCT04565925The University of Texas Medical Branch, GalvestonSildenafil for Treatment of Urinary Incontinence in Patients With Spinal Cord Injuries | 2026-12-01 |
| NCT07534696University of California, Los AngelesEvaluation of Non-Invasive Pelvic Floor Neuromuscular Stimulation for Urinary Incontinence After Prostatectomy | 2026-12-31 |
| NCT06226220University of ChicagoPercutaneous Nerve Evaluation Trial Time | 2026-12-31 |
| NCT06369922University of RochesterTENS Analgesia During Outpatient Urethral Bulking for Stress Urinary Incontinence. | 2027-01-31 |
Add all 16 to your calendar (.ics) → With an account.
Among the 293 studies in Urinary Incontinence with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Urge urinary incontinence (UUI) is a common problem in older people which vastly reduces quality of life, yet the cause and mechanism of disease are not well understood. This study will characterize brain control of the bladder in young and old continent individuals and age-matched incontinent counterparts. This will expand the investigators current knowledge of how the brain controls the bladder, how that control changes with age and disease, and suggest new targets to guide development of better treatment.
Current data suggest that bladder control comprises 3 cerebral circuits that maintain continence by suppressing the voiding reflex in the midbrain. In the UUI phenotype that responded to BFB (Biofeedback assisted pelvic floor muscle therapy), the mechanism involved enhancing deactivation of the first brain circuit (medial prefrontal cortex, mPFC) which resulted in less activation of the second circuit (which includes the midcingulate cortex). In the phenotype that was resistant to BFB, no brain changes were seen. Although the investigators have an emerging picture of the brain's role in UUI, the investigators have only rudimentary understanding of what is 'normal', i.e. how the brain normally controls the bladder. Moreover, the investigators do not know whether this control mechanism is the same across the lifespan, or whether it changes owing to the impact of aging. Thus, the investigators aims are to characterize the brain's normal role in bladder control in both young and old people, to determine the changes in brain structure and function that lead to bladder control failure (UUI), and to examine how such changes differ between young and old individuals. To address the aims, the investigators will utilize detailed neuroimaging to evaluate 80 asymptomatic women and 80 women with UUI, each group divided into young (18-45) and old (65+ years) individuals. The study will enable the investigators to define the brain's key structures, functional activity, and mechanisms involved in normal bladder control, and to identify the differences in these elements among those with UUI, both young and old.
By elucidating the mechanisms that mediate the brain's control (and loss of control) of bladder function, the proposed study should enhance the investigators working model, deepen the understanding of the impact of aging, and identify better targets for the treatment of UUI. It may thereby enable scientists to develop novel and more effective new therapies based on the revolution in neuroscience-and more hope for UUI sufferers.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Dry Groups
All Groups: 'Wet' or 'Dry'; 'Young' or 'Old'
Cognitive impairment:
Impaired mobility
o Timed up and go test ≥ 12 secs
Medical instability:
MRI incompatibility:
Medication incompatibility:
Neurological conditions:
Lower urinary tract comorbidities/treatment:
Other comorbidities:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Females with urgency urinary incontinence
Other: Brain functional MRI with simplified urodynamics
Structural: MPRAGE provides a structural image, which is used for coregistration of subjects. Structural scans are then performed including Diffusion Spectrum Imaging (DSI; microstructural), and Fluid-attenuated inversion recovery (FLAIR; white matter specific) scans. Functional: With about 50 ml in the bladder, resting state functional BOLD measurements are made, followed by functional whole-brain images while a small amount of saline is infused and withdrawn from the bladder, in 2 blocks of 4 repetitions each. Each repetition starts with a 12-scan pause, followed by infusion (6 scans = 12 s), pause (6 scans), and withdrawal (6 scans). Each block of 4 repetitions is completed by a 6 scan pause during which scanning continues. 24 ml is infused at 120 ml/min, and slightly less is withdrawn to avoid accommodation.This is repeated on an empty and full bladder along with a resting state image.
BOLD (Blood Oxygen Level Dependent) fMRI Signal Contrast - mPFC
BOLD signal contrast - voxel-wise subtraction of normalized brain activity signal measure (BOLD response) during bladder fluid withdrawal from that during bladder infusion in the a priori defined mPFC (medial prefrontal cortex) region. Since BOLD signal represents the normalized contrast in fMRI signal between two states as a proxy for cerebral blood flow, it does not have a unit. The beta value represents the amplitude of the BOLD signal difference between the two conditions. A larger beta value represents a larger difference in activity. Negative values represent greater activity in the 'withdrawal' condition.
Time frame: Baseline
BOLD (Blood Oxygen Level Dependent) fMRI Signal Contrast - Left Insula
BOLD signal contrast - voxel-wise subtraction of normalized brain activity signal measure (BOLD response) during bladder fluid withdrawal from that during bladder infusion in the a priori defined insula region. Since BOLD signal represents the normalized contrast in fMRI signal between two states as a proxy for cerebral blood flow, it does not have a unit. The beta value represents the amplitude of the BOLD signal difference between the two conditions. A larger beta value represents a larger difference in activity. Negative values represent greater activity in the 'withdrawal' condition.
Time frame: Baseline
BOLD (Blood Oxygen Level Dependent) fMRI Signal Contrast - dACC
BOLD signal contrast - voxel-wise subtraction of normalized brain activity signal measure (BOLD response) during bladder fluid withdrawal from that during bladder infusion in the a priori defined dACC (dorsal anterior cingulate cortex) region. Since BOLD signal represents the normalized contrast in fMRI signal between two states as a proxy for cerebral blood flow, it does not have a unit. The beta value represents the amplitude of the BOLD signal difference between the two conditions. A larger beta value represents a larger difference in activity. Negative values represent greater activity in the 'withdrawal' condition.
Time frame: Baseline
Participants recruited to single University of Pittsburgh site using online research registries and local geriatrics and urology clinics.
| Milestone | Young Dry | Young Wet | Old Dry | Old Wet |
|---|---|---|---|---|
| Started | 52 | 67 | 47 | 51 |
| Completed | 41 | 40 | 40 | 42 |
| Not completed | 11 | 27 | 7 | 9 |
BOLD signal contrast - voxel-wise subtraction of normalized brain activity signal measure (BOLD response) during bladder fluid withdrawal from that during bladder infusion in the a priori defined mPFC (medial prefrontal cortex) region. Since BOLD signal represents the normalized contrast in fMRI signal between two states as a proxy for cerebral blood flow, it does not have a unit. The beta value represents the amplitude of the BOLD signal difference between the two conditions. A larger beta value represents a larger difference in activity. Negative values represent greater activity in the 'withdrawal' condition.
| beta value (no units) | Young Dry | Young Wet | Old Dry | Old Wet |
|---|---|---|---|---|
| BOLD (Blood Oxygen Level Dependent) fMRI Signal Contrast - mPFC | -0.1960800 ± 0.3793670 | -0.1141890 ± 0.5451350 | -0.1688894 ± 0.3134661 | -0.1224623 ± 0.3120977 |
BOLD signal contrast - voxel-wise subtraction of normalized brain activity signal measure (BOLD response) during bladder fluid withdrawal from that during bladder infusion in the a priori defined insula region. Since BOLD signal represents the normalized contrast in fMRI signal between two states as a proxy for cerebral blood flow, it does not have a unit. The beta value represents the amplitude of the BOLD signal difference between the two conditions. A larger beta value represents a larger difference in activity. Negative values represent greater activity in the 'withdrawal' condition.
| beta value (no units) | Young Dry | Young Wet | Old Dry | Old Wet |
|---|---|---|---|---|
| BOLD (Blood Oxygen Level Dependent) fMRI Signal Contrast - Left Insula | 0.14190175 ± 0.2700647 | 0.14075584 ± 0.3971482 | 0.02884665 ± 0.2219877 | 0.11903335 ± 0.2174073 |
BOLD signal contrast - voxel-wise subtraction of normalized brain activity signal measure (BOLD response) during bladder fluid withdrawal from that during bladder infusion in the a priori defined dACC (dorsal anterior cingulate cortex) region. Since BOLD signal represents the normalized contrast in fMRI signal between two states as a proxy for cerebral blood flow, it does not have a unit. The beta value represents the amplitude of the BOLD signal difference between the two conditions. A larger beta value represents a larger difference in activity. Negative values represent greater activity in the 'withdrawal' condition.
| beta value (no units) | Young Dry | Young Wet | Old Dry | Old Wet |
|---|---|---|---|---|
| BOLD (Blood Oxygen Level Dependent) fMRI Signal Contrast - dACC | 0.06615236 ± 0.2986924 | 0.15198950 ± 0.4791248 | -0.08932060 ± 0.2751053 | 0.05305285 ± 0.2561589 |
Collected over Adverse event data was collected during study visit with intervention (MRI), i.e., the 3-4 hour visit that included catheterization and an MRI, and up to 3 days later.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Young Dry | 0/41 (0%) | 2/41 (4.9%) | 4/41 (9.8%) |
| Young Wet | 0/40 (0%) | 0/40 (0%) | 2/40 (5%) |
| Old Dry | 0/40 (0%) | 0/40 (0%) | 1/40 (2.5%) |
| Old Wet | 0/42 (0%) | 1/42 (2.4%) | 0/42 (0%) |
| Event | Young Dry | Young Wet | Old Dry | Old Wet |
|---|---|---|---|---|
| 10028050Nervous system disorders | 2/41 | 0/40 | 0/40 | 1/42 |
| Event | Young Dry | Young Wet | Old Dry | Old Wet |
|---|---|---|---|---|
| 10037175Nervous system disorders | 4/41 | 2/40 | 1/40 | 0/42 |
| Age, Categorical(Participants) | Young Dry | Young Wet | Old Dry | Old Wet | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 41 | 40 | 0 | 0 | 81 |
| >=65 years | 0 | 0 | 40 | 42 | 82 |
| Age, Continuous(years) | Young Dry | Young Wet | Old Dry | Old Wet | Total |
|---|---|---|---|---|---|
| Mean | 32.6 ± 7.5 | 36.4 ± 6.7 | 69.4 ± 3.5 | 72.1 ± 5.4 | 52.7 ± 10.2 |
| Sex: Female, Male(Participants) | Young Dry | Young Wet | Old Dry | Old Wet | Total |
|---|---|---|---|---|---|
| Female | 41 | 40 | 40 | 42 | 163 |
| Male | 0 | 0 | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | Young Dry | Young Wet | Old Dry | Old Wet | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 1 | 2 | 0 | 0 | 3 |
| Not Hispanic or Latino | 40 | 38 | 39 | 41 | 158 |
| Unknown or Not Reported | 0 | 0 | 1 | 1 | 2 |
| Race (NIH/OMB)(Participants) | Young Dry | Young Wet | Old Dry | Old Wet | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 3 | 1 | 0 | 0 | 4 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 4 | 9 | 2 | 5 | 20 |
| White | 30 | 26 | 38 | 36 | 130 |
| More than one race | 3 | 3 | 0 | 1 | 7 |
| Unknown or Not Reported | 1 | 1 | 0 | 0 | 2 |
| Region of Enrollment(participants) | Young Dry | Young Wet | Old Dry | Old Wet | Total |
|---|---|---|---|---|---|
| United States | 41 | 40 | 40 | 42 | 163 |
| No of leaks/24h(leaks /24hours on 3 day bladder diary) | Young Dry | Young Wet | Old Dry | Old Wet | Total |
|---|---|---|---|---|---|
| Mean | 0 ± 0 | 3.79 ± 2.26 | 0 ± 0 | 3.97 ± 2.13 | 1.95 ± 2.48 |
| BMI(kg/m^2) | Young Dry | Young Wet | Old Dry | Old Wet | Total |
|---|---|---|---|---|---|
| Mean | 27.5 ± 7.8 | 33.2 ± 7.9 | 25.4 ± 5.2 | 33.1 ± 13.4 | 29.8 ± 9.7 |
1 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — All of the individual participant data collected during the trial, after de-identification may be shared with other researchers.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Following publication, no end date
Access criteria: Any purpose
Ran from Dec 2020 to primary completion in Jul 2025, 55 months.
Results were first posted in Oct 2026, 1 year 2 months after primary completion.
Of 303 non-industry interventional studies with no phase under Urinary Incontinence, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 37. This study's 55 months is above that.
Counting every sponsor, half of 366 studies reached it within 15 months; a quarter within 7 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.